"Gonorrhoea is on the rise around the world, with more than 82m infections globally each year and particularly high rates in Africa and countries in the World Health Organization's Western Pacific region, which reaches from Mongolia and China to New Zealand. Cases in England are at a record high, and rates in Europe were three times higher in 2023 than in 2014. Health officials are concerned about an increase in drug-resistant strains of the bacterium, with the WHO designating it a priority pathogen."
"Dr Tereza Kasaeva, director of the WHO's sexually transmitted infections department, said: The approval of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available. Zoliflodacin, also known by the brand name Nuzolvence, was approved by the US Food and Drug Administration on 12 December for use against gonorrhoea, which can cause serious health problems, including infertility."
Gonorrhoea infections exceed 82 million globally each year, with particularly high rates in Africa and the WHO Western Pacific region. Cases in England are at a record high and European rates tripled between 2014 and 2023. Drug-resistant strains are increasing, prompting the WHO to designate Neisseria gonorrhoeae as a priority pathogen. WHO surveillance reported resistance to ceftriaxone rising from 0.8% to 5% and to cefixime from 1.7% to 11% between 2022 and 2024. Two new antibiotics, zoliflodacin (Nuzolvence) and gepotidacin, received recent regulatory approval, and targeted use aims to treat resistant infections and slow further resistance development.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]